ArticleJournal of musculoskeletal & neuronal interactions2020
Expression changes of IL-17 in zoledronic acid combined with PVP technology in the treatment of postmenopausal osteoporotic vertebral compression fracture and its predictive value of relapse.
Article in Journal of musculoskeletal & neuronal interactions, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.
- Risk factors for new vertebral compression fracture following percutaneous vertebral augmentation: a systematic review and meta-analysis based on multivariate logistic regression analysis.Journal of orthopaedic surgery and research · 2025Pooled it
- Risk factors of vertebral re-fracture after PVP or PKP for osteoporotic vertebral compression fractures, especially in Eastern Asia: a systematic review and meta-analysis.Journal of orthopaedic surgery and research · 2022Pooled it
- Article
- Interleukin Concentrations in Bone Marrow Fluid and MRI Prognostic Findings in Osteoporotic Vertebral Fractures.Cureus · 2025Article
- Causal impact of DNA methylation on refracture in elderly individuals with osteoporosis - a prospective cohort study.BMC musculoskeletal disorders · 2024Article
- Mechanisms of gut homeostasis regulating Th17/Treg cell balance in PMOP.Frontiers in immunology · 2024Review
- Effects of the obstruction of erector spinae plane in affected people undergoing percutaneous vertebroplasty.BMC surgery · 2023Article
- Osteoporosis in patients with rheumatoid arthritis is associated with serum immune regulatory cellular factors.Clinical rheumatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expression of interleukin-17 (IL-17) in zoledronic acid combined with PVP technology for patients with postmenopausal osteoporotic vertebral compression fracture (OVCF) and its predictive value for relapse.
methods101 OVCF patients treated in our hospital from April 2013 to January 2015 were collected as a research group and treated by zoledronic acid combined with PVP technology. 80 healthy people with physical examination were assigned to the control group. ELISA was used to detect the expression of IL-17 in serum of the two groups. Patients were followed up for 2 years. The expression of IL-17 before treatment was compared between patients with relapse and patients without relapse. The predictive value of IL-17 in relapse was drawn according to ROC curve.
resultsBefore treatment, the expression of IL-17 in the research group increased significantly (p<0.05). After treatment, the expression of IL-17 in the research group decreased significantly (p<0.05). The level of IL-17 in patients with relapse was significantly higher than that in patients without relapse (p<0.05).
conclusionsIL-17 is highly expressed in postmenopausal patients with osteoporotic vertebral compression fracture and is expected to be a potential predictor of relapse in postmenopausal patients with OVCF.
Indexed as
Identifiers
33265085PMC7716692W3106812305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.